[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-intestinal-metaplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-intestinal-metaplasia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,74,105,129,149,170,188],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100637944","ai-based-risk-prediction-model-for-upper-digestive-tract-cancer-100637944",false,"NCT07605312","AI-Based Risk Prediction Model for Upper Digestive Tract Cancer","Development of Artificial Intelligence Risk Prediction Model for Upper Digestive Tract Cancer Using High Resolution Endoscopic Image, Digital Pathology, Genetics, and Oro-gastro-intestinal Microbiota.","Inclusion Criteria:\n\n* Patients undergoing upper gastrointestinal endoscopy.\n* Patients with at least one of the following conditions or indications:\n\n  * Previous or current Helicobacter pylori infection (confirmed by serology, histopathology, urea breath test, rapid urease test, or stool antigen test);\n  * Dyspeptic symptoms;\n  * Gastroesophageal reflux disease;\n  * History of oral, oropharyngeal, or hypopharyngeal squamous cell carcinoma;\n  * Barrett's esophagus;\n  * Gastric premalignant lesions (intestinal metaplasia or atrophic gastritis);\n  * Gastric subepithelial lesions.\n\nExclusion Criteria:\n\n\\-",true,"ALL","40 Years",{"count":20,"type":21},10000,"ESTIMATED","10 Years","OBSERVATIONAL","Upper digestive tract cancers are often preceded by pre-malignant lesions, but there is limited evidence regarding optimal risk prediction models and screening strategies for disease progression and cancer development. This prospective multicenter cohort study aims to establish a longitudinal database integrating clinical information, endoscopic findings, pathology, genetics, epigenetics, and gastrointestinal microbiota data from subjects undergoing upper digestive tract endoscopy.\n\nThe study will develop explainable artificial intelligence (AI)-based risk prediction models to identify factors associated with disease progression, treatment response, and cancer development. Participants will be followed longitudinally to evaluate changes in lesion severity and clinical outcomes.",[26,27,28,29,30,31],"Gastric Cancer (GC)","Premalignant Lesion","Gastric Intestinal Metaplasia","Atrophic Gastritis","Dysplasia Stomach","Esophageal Cancer (EsC)","NOT_YET_RECRUITING","2026-05-25",{"date":35,"type":36},"2026-05-28","ACTUAL",{"date":38,"type":21},"2026-05-18",{"date":40,"type":21},"2030-05-18",{"name":42,"class":43},"National Taiwan University Hospital","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100561460","phase-2-reverse-intestinal-metaplasia-in-the-stomach-revise-100561460","NCT06590454","REVerse Intestinal Metaplasia in the Stomach (REVISE)","Therapeutic Intervention to Reverse Gastric Precancer","REVISE","Inclusion Criteria:\n\n* Adults (including men, women, and non-binary individuals) over age 18 with known GIM with at least one high-risk feature (extensive vs limited, incomplete or mixed-type GIM, family history of stomach cancer),\n* Ability to provide informed consent,\n* Evidence of prior but not active H. pylori infection\n\nExclusion Criteria:\n\n* Active gastric cancer diagnosis,\n* High-risk of bleeding complications due to anticoagulants or underlying medical condition,\n* Pregnancy (which is a contraindication to non-emergent endoscopy due to anesthesia risks)","18 Years",{"count":54,"type":21},32,"INTERVENTIONAL",[57],"PHASE2","This study is designed to test the use of Pyrvinium vs placebo as a treatment for gastric intestinal metaplasia with features associated with increased risk of cancer. Response will be determined by assessing the extent and quality of the gastric intestinal metaplasia before and after treatment.\n\nA secondary aim will be to generate gastric organoids from patient-derived samples to test the effects of pyrvinium in vitro in patient-derived samples, and also to identify new drugs that may help reverse gastric intestinal metaplasia.",[28,60],"Gastric Precancer",[28,62],"Pyrvinium","RECRUITING","2026-02-10",{"date":66,"type":36},"2026-02-12",{"date":68,"type":36},"2025-12-15",{"date":70,"type":21},"2026-10-01",{"name":72,"class":43},"Katherine Garman",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":16,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":83,"conditions":84,"keywords":89,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},"100544535","a-study-collecting-health-information-to-understand-and-prevent-gastric-cancer-100544535","NCT06370143","A Study Collecting Health Information to Understand and Prevent Gastric Cancer","Gastric Cancer Prevention: Understanding Precursor Lesions and Risk Factors for Progression to Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Able to read and understand English and Spanish\n* Meet criteria for one of three potentially eligible study populations:\n\n  * Individuals with gastric atrophy, gastric intestinal metaplasia, or dysplasia: Had a previous diagnosis of or have been diagnosed by the investigation team with gastric atrophy, gastric intestinal metaplasia, or dysplasia of the gastric mucosa on pathology review from an endoscopic biopsy. Individuals who have a prior history of early gastric cancer may be included, if they were treated endoscopically and have no evidence of disease. Individuals who have a prior history of a cancer other than upper gastrointestinal cancer may also be included, if they have no evidence of disease for at least 1 year prior to study enrollment and are not undergoing active treatment for any malignancy at any time throughout the study period\n  * Healthy controls (average risk): Individuals with no history of cancer or gastric precursor lesions undergoing a clinically indicated endoscopy at MSK for workup or dyspepsia or reflux\n  * Gastric cancer cases: Individuals with a known diagnosis of early gastric adenocarcinoma undergoing surgical resection at MSK\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Women who are pregnant (may be enrolled after delivery)\n* Individuals with a prior history of upper gastrointestinal surgery or a prior cancer who are undergoing active treatment for malignancy or have been diagnosed within 1 year prior to the study enrollment or with pancreatic cancer. (This does not include incidentally diagnosed primary gastric adenocarcinoma identified during study follow up. Individuals diagnosed with gastric carcinoid limited to the stomach will also be included, given their ongoing parallel risk for gastric adenocarcinoma.)\n* Have severe comorbidities with expected survival time \\\u003C2 years or which would prevent them from undergoing routine elective EGD (at the discretion of the patient's provider and the study team)\n* Individuals having Hereditary Diffuse Gastric Cancer Syndrome, mutations including CDH1 and CTNNA1, or more than one genetic mutation\n* Exclude high risk esophageal and duodenal lesions including:\n\n  * Duodenal Adenoma\n  * Dysplasia or cancer at the esophagus or gastroesophageal junction\n* Patients with an increased risk for biopsies during EGD, such as those with clotting disorders.",{"count":82,"type":21},3200,"The purpose of this study is to create a registry of participants with precursor lesions for gastric cancer, including gastric atrophy, intestinal metaplasia, and dysplasia. Normal controls and individuals with gastric cancer for comparison of baseline characteristics will also be enrolled.",[85,28,86,87,88],"Gastric Atrophy","Dysplasia","Gastric Adenocarcinoma","Gastric Cancer",[90,91,92,28,93,94,95],"Gastric cancer","gastric adenocarcinoma","gastric atrophy","dysplasia","Memorial Sloan Kettering Cancer Center","24-083","2026-01-28",{"date":98,"type":36},"2026-01-30",{"date":100,"type":36},"2024-04-11",{"date":102,"type":21},"2036-04-11",{"name":94,"class":43},7,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":55,"phases":115,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100563022","phase-4-efficacy-and-safety-of-ursodeoxycholic-acid-in-reversing-gastric-intestinal-metaplasia-100563022","NCT06610760","Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia","Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia: A Multicenter, Randomized, Placebo-Controlled Trial","Inclusion Criteria:\n\n* patients aged from 18 to 75 years old.\n* patients with OLGIM stage Ⅱ-Ⅳ diagnosed by upper gastrointestinal endoscopy and histopathological examination within the last 3 months.\n* patients without Helicobacter pylori infection, including patients who had successful Helicobacter pylori eradication before enrollment.\n\nExclusion Criteria:\n\n* a history of regular use (defined as at least once per week) of non-steroidal anti-inflammatory drugs (NSAIDs) and\u002For statins.\n* a history of stomach surgery (including endoscopic submucosal dissection and endoscopic mucosal resection) or previously diagnosed malignant tumor.\n* a history of heart failure, renal failure, liver cirrhosis or chronic hepatic failure; patients with contraindications or allergies to the drugs in this study.\n* breastfeeding or pregnancy.\n* a history of substance abuse or alcohol abuse within the past one year.\n* patients with severe mental illness.\n* refusal to undergo drug treatment.\n* refusal to sign informed consent.","75 Years",{"count":114,"type":21},196,[116],"PHASE4","The goal of this clinical trial is to investigate the efficacy of ursodeoxycholic acid in treating gastric intestinal metaplasia in Helicobacter pylori-negative adults. It will also learn about the safety of ursodeoxycholic acid. The main questions it aims to answer are:\n\nDoes ursodeoxycholic acid promote the regression of IM in individuals without Helicobacter pylori infection? What medical problems do participants experience when taking ursodeoxycholic acid? Researchers will compare ursodeoxycholic acid to a placebo (a look-alike substance that contains no drug) to see if ursodeoxycholic acid is effective in treating gastric intestinal metaplasia.\n\nParticipants will:\n\nTake ursodeoxycholic acid or a placebo every day for 6 months. Visit the clinic once every 4 weeks for checkups and tests.",[28],"2025-12-04",{"date":121,"type":36},"2025-12-05",{"date":123,"type":36},"2024-11-12",{"date":125,"type":21},"2026-10-31",{"name":127,"class":43},"Yongquan Shi",6,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":55,"phases":137,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":73},"100609000","efficacy-of-an-ai-system-in-training-endoscopists-to-assess-gastric-intestinal-metaplasia-via-the-eggim-score-100609000","NCT07208864","Efficacy of an AI System in Training Endoscopists to Assess Gastric Intestinal Metaplasia Via the EGGIM Score","Efficacy of an AI System in Training Endoscopists to Assess Gastric Intestinal Metaplasia Via the EGGIM Score: A Randomized Controlled Trial","Inclusion Criteria:\n\nEndoscopists who have performed ≥50 image-enhanced endoscopy (IEE) procedures per year and demonstrated competency in performing standardized IEE.\n\nExclusion Criteria:\n\nEndoscopists who participated in data acquisition or were unblinded to patients' identifiable information and clinical data.",{"count":5,"type":21},[138],"NA","This prospective randomized controlled trial with a crossover design incorporated image-enhanced endoscopy (IEE) videos demonstrating complete standardized examinations of five standard gastric areas (antrum greater curvature, antrum lesser curvature, incisura, corpus lesser curvature, and corpus greater curvature). Endoscopists were stratified by experience level and randomly assigned to either the AI-assisted scoring first group, which performed EGGIM scoring with AI assistance in the initial phase followed by conventional scoring after a washout period, or the conventional scoring first group, which completed the assessments in reverse order. The study primarily evaluated the training efficacy of the EGGIM-AI system for improving endoscopists' EGGIM scoring performance by comparing diagnostic accuracy metrics including the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity between groups at different study phases, with histopathological results serving as the gold standard.",[28],"2025-11-27",{"date":121,"type":36},{"date":144,"type":21},"2025-11-30",{"date":146,"type":21},"2026-12-31",{"name":148,"class":43},"Qilu Hospital of Shandong University",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":112,"enrollmentInfo":156,"targetDuration":4,"studyType":55,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":4},"100602895","phase-4-efficacy-and-safety-of-berberine-for-gastric-intestinal-metaplasia-100602895","NCT07129460","Efficacy and Safety of Berberine for Gastric Intestinal Metaplasia","Efficacy and Safety of Berberine for Gastric Intestinal Metaplasia: a Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial","Inclusion Criteria:\n\n* patients aged from 18 to 75 years old.\n* patients with OLGIM stage Ⅱ-Ⅳ diagnosed by upper gastrointestinal endoscopy and histopathological examination within the last 3 months.\n* patients without Helicobacter pylori infection, including patients who had successful Helicobacter pylori eradication before enrollment.\n\nExclusion Criteria:\n\n* a history of regular use (defined as at least once per week) of non-steroidal anti-inflammatory drugs (NSAIDs) and\u002For statins\u002For Metformin.\n* a history of stomach surgery (including endoscopic submucosal dissection and endoscopic mucosal resection) or previously diagnosed malignant tumor.\n* a history of heart failure, renal failure, liver cirrhosis or chronic hepatic failure; patients with contraindications or allergies to the drugs in this study.\n* breastfeeding or pregnancy.\n* a history of substance abuse or alcohol abuse within the past one year.\n* patients with severe mental illness.\n* refusal to undergo drug treatment.\n* refusal to sign informed consent.",{"count":157,"type":21},204,[116],"The goal of this clinical trial is to investigate the efficacy of Berberine in treating gastric intestinal metaplasia in Helicobacter pylori-negative adults. It will also learn about the safety of Berberine. The main questions it aims to answer are:\n\nDoes Berberine promote the regression of IM in individuals without Helicobacter pylori infection? What medical problems do participants experience when taking Berberine? Researchers will compare Berberine to a placebo (a look-alike substance that contains no drug) to see if uBerberine is effective in treating gastric intestinal metaplasia.\n\nParticipants will:\n\nTakeBerberine or a placebo every day for 6 months. Visit the clinic once every 4 weeks for checkups and tests.",[28],"2025-08-26",{"date":163,"type":36},"2025-09-04",{"date":165,"type":21},"2025-10-01",{"date":167,"type":21},"2027-05-01",{"name":169,"class":43},"Xijing Hospital of Digestive Diseases",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":112,"enrollmentInfo":176,"targetDuration":4,"studyType":55,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":187,"locationsCount":73},"100562984","phase-4-efficacy-and-safety-of-weifuchun-tablet-in-reversing-gastric-intestinal-metaplasia-100562984","NCT06610266","Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia","Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia: A Multi-center, Open-label, Randomized Controlled Trial",{"count":177,"type":21},400,[116],"The goal of this clinical trial is to investigate the efficacy and safety of Weifuchun tablet in treating gastric intestinal metaplasia in Helicobacter pylori-negative adults. The main questions it aims to answer are: Does Weifuchun tablet promote the regression of gastric intestinal metaplasia in individuals without Helicobacter pylori infection? What medical problems do participants experience when taking Weifuchun tablet? Researchers will compare the effectiveness of Weifuchun tablet in treating gastric intestinal metaplasia with that of folic acid, as suggested by the Chinese consensus on management of gastric epithelial precancerous conditions and lesions (2020). Participants will: Take Weifuchun tablets or folic acid every day for 6 months. Visit the clinic once every 4 weeks for checkups and tests.",[28],"2025-07-01",{"date":183,"type":36},"2025-07-02",{"date":185,"type":36},"2025-02-28",{"date":125,"type":21},{"name":127,"class":43},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":16,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":73},"100304969","surveillance-of-patients-with-precancerous-lesions-of-the-stomach-100304969","NCT03250091","Surveillance of Patients With Precancerous Lesions of the Stomach","Surveillance Strategies of Patients With Precancerous Conditions and Lesions in the Stomach","Inclusion Criteria:\n\nPatients undergoing upper endoscopy Motivation to participate in the study Signed consent\n\nExclusion Criteria:\n\nKnown gastric cancer Unwillingness or inability to co-operate",{"count":196,"type":21},2000,"The project will aim to identify and determine subgroups of patients with different risks of progression to gastric cancer and to assess appropriate follow-up intervals. Implementing risk stratification only high risk individuals will be offered and performed endoscopic surveillance.",[88,28,85,199],"Gastric Dysplasia",[201,202,203,92,204],"gastric precancerous lesions","gastric cancer","gastric intestinal Metaplasia","gastric dysplasia","2018-08-20",{"date":207,"type":36},"2018-08-21",{"date":209,"type":36},"2017-06-19",{"date":211,"type":21},"2027-12",{"name":213,"class":43},"University of Latvia"]